DNA methyltransferase inhibitor CDA-2 synergizes with high-dose thiotepa and paclitaxel in killing breast cancer stem cells.

No abstract is available for this paper.

• Publication year

  2011

• Venue

  Frontiers in Bioscience

• Publication date

  Unknown publication date

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.2741/E239PMID 21196304
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Cyclopamine inhibition of human breast cancer cell growth independent of Smoothened (Smo)

  2009cited by this paper
• CDA-II, a urinary preparation, induces growth arrest and apoptosis of human leukemia cells through inactivation of nuclear factor-kappaB in a caspase-dependent manner.

  2009cited by this paper
• The inhibitory effect of uroacitide against human gastric cancer cell SGC7901 in vitro

  2008cited by this paper
• Human urine extract CDA-2 induces apoptosis of myelodysplastic syndrome-derived MUTZ-1 cells through the PI3K/Akt signaling pathway in a caspase-3-dependent manner

  2008cited by this paper
• Hedgehog inhibition prolongs survival in a genetically engineered mouse model of pancreatic cancer

  2008cited by this paper
• New developments in medulloblastoma treatment: the potential of a cyclopamine–lovastatin combination

  2008cited by this paper
• The CD44+/CD24- phenotype is enriched in basal-like breast tumors

  2008cited by this paper
• The Effect of Uroacitide on the Proliferation and Differentiation of Human Endometrial Carcinoma Cell Line EAC

  2008cited by this paper
• Implications of the cancer stem-cell hypothesis for breast cancer prevention and therapy.

  2008cited by this paper
• Triple-negative high-risk breast cancer derives particular benefit from dose intensification of adjuvant chemotherapy: results of WSG AM-01 trial.

  2008influential reference
• Temozolomide preferentially depletes cancer stem cells in glioblastoma.

  2008cited by this paper
• Basal-Like Breast Cancer Defined by Five Biomarkers Has Superior Prognostic Value than Triple-Negative Phenotype

  2008cited by this paper
• Origins of breast cancer subtypes and therapeutic implications

  2007cited by this paper
• Gene expression profiling and histopathological characterization of triple-negative/basal-like breast carcinomas

  2007cited by this paper
• Hedgehog signaling maintains a tumor stem cell compartment in multiple myeloma

  2007cited by this paper
• Interplay of distinct growth factors during epithelial mesenchymal transition of cancer progenitor cells and molecular targeting as novel cancer therapies.

  2007cited by this paper
• The prognostic role of a gene signature from tumorigenic breast-cancer cells.

  2007cited by this paper
• let-7 regulates self renewal and tumorigenicity of breast cancer cells.

  2007cited by this paper
• Recent advances in cancer stem/progenitor cell research: therapeutic implications for overcoming resistance to the most aggressive cancers

  2007cited by this paper
• HEDGEHOG-GLI1 signaling regulates human glioma growth, cancer stem cell self-renewal, and tumorigenicity.

  2007cited by this paper
• Cyclopamine‐Mediated Hedgehog Pathway Inhibition Depletes Stem‐Like Cancer Cells in Glioblastoma

  2007cited by this paper
• Histone deacetylases: target enzymes for cancer therapy

  2007cited by this paper
• Molecular definition of breast tumor heterogeneity.

  2007cited by this paper
• Gene expression profiling of breast cell lines identifies potential new basal markers

  2006cited by this paper
• Hedgehog signaling and Bmi-1 regulate self-renewal of normal and malignant human mammary stem cells.

  2006cited by this paper
• A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes.

  2006cited by this paper
• Exploiting the role of O6-methylguanine-DNA-methyltransferase (MGMT) in cancer therapy.

  2006cited by this paper
• Tumour stem cell-targeted treatment: elimination or differentiation.

  2006cited by this paper
• CD44+/CD24- breast cancer cells exhibit enhanced invasive properties: an early step necessary for metastasis

  2006cited by this paper
• Prospective identification of tumorigenic prostate cancer stem cells.

  2005cited by this paper
• Differentiation of Pheochromocytoma PC12 Cells Induced by Human Urine Extract and the Involvement of the Extracellular Signal–Regulated Kinase Signaling Pathway

  2005cited by this paper
• Comparison of rapidly cycled tandem high-dose chemotherapy plus peripheral-blood stem-cell support versus dose-dense conventional chemotherapy for adjuvant treatment of high-risk breast cancer: results of a multicentre phase III trial.

  2005influential reference
• Tumour stem cells and drug resistance

  2005cited by this paper
• The molecular repertoire of the 'almighty' stem cell

  2005cited by this paper
• The effects of histone deacetylase inhibitors on heterochromatin: implications for anticancer therapy?

  2005cited by this paper
• Mammary stem cells, self-renewal pathways, and carcinogenesis

  2005cited by this paper
• A tumorigenic subpopulation with stem cell properties in melanomas.

  2005cited by this paper
• Phase III clinical trials of the cell differentiation agent-2 (CDA-2): Therapeutic efficacy on breast cancer, non-small cell lung cancer and primary hepatoma1

  2005cited by this paper
• Identification of human brain tumour initiating cells

  2004cited by this paper
• BRCA1 functions as a differential modulator of chemotherapy-induced apoptosis.

  2003cited by this paper
• Conventional adjuvant chemotherapy with or without high-dose chemotherapy and autologous stem-cell transplantation in high-risk breast cancer.

  2003influential reference
• Breast cell invasive potential relates to the myoepithelial phenotype

  2003cited by this paper
• Prospective identification of tumorigenic breast cancer cells

  2003cited by this paper
• Homology-directed dna repair, mitomycin-c resistance, and chromosome stability is restored with correction of a Brca1 mutation.

  2001cited by this paper
• Current options in treatment of anthracycline-resistant breast cancer.

  1999cited by this paper

• COVID-19 Associated Ischemic Stroke and Hemorrhagic Stroke: Incidence, Potential Pathological Mechanism, and Management

  2020cites this paper
• Self-renewal signaling pathways in breast cancer stem cells.

  2019cites this paper
• Human Urine Extract Cell Differentiation Agent 2 Protects PC12 Cells from Serum Deprivation-Induced Apoptosis Accompanied with Priming of Extracellular Signal-Regulated Kinase Activation and Differentiation Induction

  2018cites this paper
• CYP1A1 genetic polymorphism is a promising predictor to improve chemotherapy effects in patients with metastatic breast cancer treated with docetaxel plus thiotepa vs. docetaxel plus capecitabine

  2018cites this paper
• Breast Cancer Stem Cells and the Move Toward High-Resolution Stem Cell Systems

  2017cites this paper
• Evaluation of function and recovery of adipose-derived stem cells after exposure to paclitaxel.

  2017cites this paper
• Low doses of paclitaxel enhance liver metastasis of breast cancer cells in the mouse model

  2016cites this paper
• Prospective study of cyclophosphamide, thiotepa, carboplatin combined with adoptive DC-CIK followed by metronomic cyclophosphamide therapy as salvage treatment for triple negative metastatic breast cancers patients (aged <45)

  2015cites this paper
• The prognostic values of CYP2B6 genetic polymorphisms and metastatic sites for advanced breast cancer patients treated with docetaxel and thiotepa

  2015cites this paper
• Paclitaxel impairs adipose stem cell proliferation and differentiation.

  2015cites this paper
• Selections of appropriate regimen of high-dose chemotherapy combined with adoptive cellular therapy with dendritic and cytokine-induced killer cells improved progression-free and overall survival in patients with metastatic breast cancer: reargument of such contentious therapeutic preferences

  2013cites this paper
• Enrichment and Selective Targeting of Cancer Stem Cells in Colorectal Cancer Cell Lines

  2013cites this paper
• CDA-2 induces cell differentiation through suppressing Twist/SLUG signaling via miR-124 in glioma

  2012cites this paper
• DNA methyltransferase inhibitor CDA-II inhibits myogenic differentiation.

  2012cites this paper
• De-mystifying the epigenetic free for all : pharmacophore modeling for epigenetic cancer therapy

  2011cites this paper